Apollomics Inc. Class A Ordinary Shares

Apollomics Inc. has entered into definitive subscription agreements for a private placement valued at approximately $10 million. The transaction includes cash subscriptions for 533,334 Class A Shares at $15.00 per share, generating about $8.0 million in gross proceeds, and the conversion of a $2 million unsecured Convertible Promissory Note held by CEO Hung-Wen (Howard) Chen into 166,667 Class A Shares at $12.00 per share. Several company executives and directors, including Chen, CFO Peter Kuan-How Lin, and COO Yi-Kuei (Alex) Chen through Maxpro Investment Co., Ltd., participated in the cash portion alongside unaffiliated accredited investors. No placement agents or underwriters were involved, and no commissions or finder's fees are payable. The deal is expected to close on or about August 14, 2026, subject to customary conditions.

Biotech stocks surged Thursday, led by CareDx which soared over 35% after Medicare finalized a policy confirming coverage for its transplant surveillance portfolio, including AlloSure Kidney and AlloMap Heart, effective August 30, 2026. AtaiBeckley jumped more than 33% on news it will be acquired by Eli Lilly in a deal valued at up to $3.8 billion, comprising $2.8 billion in upfront cash and up to $1.0 billion in contingent value rights tied to milestones for its depression treatments BPL-003 and VLS-01. Abbott Laboratories gained over 10% after reporting second-quarter net sales of $12.6 billion, a 13% increase, and raising its full-year adjusted earnings per share outlook to a range of $5.45 to $5.60. Apollomics added another 21%, bringing its weekly gain to more than 60%, as its lead candidate Vebreltinib advances in a Phase 2 trial for clear cell sarcoma and the company regained Nasdaq compliance. Virax Biolabs rose 13% after its CEO highlighted a narrowed net loss of $5.0 million, a $3.3 million capital raise, and a supply agreement with Fosun Diagnostics, while Entera Bio climbed over 12% ahead of a planned Phase 3 trial for its oral osteoporosis tablet EB613.

Apollomics shares surged over 22% on Wednesday after the company regained compliance with Nasdaq's Market Value of Listed Securities requirement. The clinical-stage firm, whose lead program is the c-Met inhibitor Vebreltinib for non-small cell lung cancer, was notified on July 8 that the matter had been closed. Other notable movers included Iovance Biotherapeutics, up more than 20% ahead of its second-quarter report, where Amtagvi revenue is expected between $79 million and $81 million, about 23% higher than in the fourth quarter of 2025. AVITA Medical rose over 17% before its own second-quarter update, while Annexon gained more than 17% in anticipation of a presentation at the American Society of Retina Specialists meeting and upcoming pivotal data from its Phase 3 ARCHER II trial in geographic atrophy. Veradermics climbed over 12% after reporting positive Phase 2 results for its oral minoxidil formulation VDPHL01 in female pattern hair loss, with 88.9% of once-daily patients reporting improved or much improved outcomes by month six.